GlassScriptPhysician profile
Ira Guttentag
NPI 1841301355
$5,210.49
in general payments reported to CMS, 2019-2025
29 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $721 · 2021: $1,525 · 2022: $161 · 2023: $328 · 2024: $598 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mvp Orthopedics INC | $1,807.25 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $854.61 | 2023-2025 | Euflexxa |
| Zimmer Biomet Holdings, INC. | $694.07 | 2019-2025 | Arthroscopy Instrument Systems |
| Stryker Corporation | $642.97 | 2019-2025 | Axsos, Variax, Augment Injectable |
| Smith+Nephew, INC. | $463.14 | 2019-2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Renasys Go V2 Home, Pico 14 |
| Depuy Synthes Sales INC. | $127.36 | 2019-2024 | Monovisc, Orthovisc, Truespan Orthocord |
| Coastal Medical Technologies LLC | $70.41 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $54.11 | 2025 | |
| Ermi LLC | $49.23 | 2019-2020 | |
| Horizon Therapeutics Plc | $44.57 | 2019 | |
| Bioventus LLC | $42.73 | 2019-2024 | Gelsyn-3 |
| Vericel Corporation | $41.24 | 2019-2025 | |
| Heron Therapeutics, INC. | $30.05 | 2021 | |
| Sanara Medtech INC. | $28.55 | 2024 | Celleraterx |
| Acera Surgical, INC. | $24.71 | 2025 | Restrata Wound Matrix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $24.28 | 2019-2020 | |
| Kci USA, INC. | $23.66 | 2020 | |
| Biocomposites INC | $19.73 | 2019 | |
| Medtronic, INC. | $18.27 | 2025 | Endurant Iis |
| Forte Bio-Pharma LLC | $17.40 | 2019 | |
| Integra Lifesciences Corporation | $17.24 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.91 | 2023 | Iovera, Zilretta |
| Fidia Pharma USA INC. | $16.43 | 2025 | Triluron, Hymovis |
| Heraeus Medical, LLC. | $14.88 | 2020 | |
| Avanos Medical | $14.39 | 2022 | |
| Orthogenrx INC. | $14.17 | 2019 | |
| Theragen, INC. | $13.13 | 2023 | Actastim-S |
| Sanofi-Aventis U.S. LLC | $12.75 | 2019 | |
| Skeletal Dynamics INC | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Guttentag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.